Clinical Approach to Hair Thinning
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of hair thinning in women
Hair thinning is one of the most common dermatological complaints encountered in gynecological practice, affecting approximately 50% of women by age 50. Female pattern hair loss, the most prevalent form, impacts an estimated 30 million women in the United States alone. Despite its high prevalence, hair loss remains significantly underdiagnosed and undertreated, with profound psychological consequences including depression, anxiety, and diminished quality of life. In gynecological settings, hair thinning often serves as an important clinical marker for underlying hormonal disorders such as polycystic ovary syndrome, thyroid dysfunction, or perimenopausal hormonal changes.
Definition
Androgenic alopecia (also termed female pattern hair loss) is a progressive, non-scarring form of hair loss characterized by gradual reduction in hair density and diameter, primarily affecting the central scalp while preserving the frontal hairline. It results from the interaction between genetic susceptibility, androgen hormones, and local follicular factors, leading to progressive miniaturization of hair follicles.
Key Epidemiology
- Prevalence increases with age: 12% in women aged 20-29, 25% in women aged 40-49, 41% in women aged 50-59, and over 50% in women older than 70
- Global burden: Affects approximately 50% of women during their lifetime
- PCOS association: Hair loss occurs in 20-25% of women with polycystic ovary syndrome
- Psychological impact: Up to 70% of affected women report significant emotional distress
Classification by Duration and Onset
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute | Less than 6 months | Telogen effluvium (postpartum, post-illness, medication-induced), acute stress, crash dieting | Often reversible; identify and address trigger |
| Subacute | 6 to 12 months | Chronic telogen effluvium, early androgenic alopecia, thyroid disorders, iron deficiency | Requires workup for underlying systemic cause |
| Chronic | Greater than 12 months | Female pattern hair loss, chronic telogen effluvium, cicatricial alopecia, PCOS | May be progressive; early treatment improves outcomes |
Classification by Pattern (Ludwig Scale for Female Pattern Hair Loss)
| Grade | Description | Clinical Appearance | Treatment Implications |
|---|---|---|---|
| Grade I (Mild) | Perceptible thinning on crown | Widening of central part, preserved frontal hairline, visible scalp through hair | Best response to medical therapy; early intervention recommended |
| Grade II (Moderate) | Pronounced rarefaction | Marked decrease in hair density on crown, clearly visible scalp, preserved frontal fringe | Medical therapy beneficial; may consider adjunctive treatments |
| Grade III (Severe) | Total baldness on crown | Complete denudation of crown, thin frontal rim remains | Limited response to medical therapy; surgical options may be considered |
Classification by Pattern Type
Diffuse Pattern (Ludwig Pattern)
Description: Diffuse thinning over the crown and mid-scalp with preservation of the frontal hairline. This is the most common pattern in women and is characteristic of female pattern hair loss.
Clinical implication: Suggests hormonal influence, particularly androgens. Often associated with normal androgen levels but increased follicular sensitivity.
Frontal/Male Pattern (Hamilton Pattern)
Description: Bitemporal recession and vertex thinning similar to male pattern baldness. Frontal hairline recession is prominent.
Clinical implication: More suggestive of hyperandrogenism. Warrants investigation for PCOS, adrenal disorders, or androgen-secreting tumors.
Christmas Tree Pattern (Olsen Pattern)
Description: Widening of central part that is broader at the frontal hairline and tapers toward the vertex, creating a triangular or “Christmas tree” appearance.
Clinical implication: Variant of female pattern hair loss; may be more common in younger women.
Diffuse Shedding (Telogen Effluvium Pattern)
Description: Generalized thinning affecting the entire scalp without a specific pattern of distribution. Often acute onset with noticeable increased shedding.
Clinical implication: Points toward systemic trigger (hormonal, nutritional, stress, medication). Often reversible once trigger addressed.
Classification by Life Stage and Hormonal Context
| Life Stage | Hormonal Context | Common Causes | Key Considerations |
|---|---|---|---|
| Reproductive Age (18-40) | Cycling hormones, possible hyperandrogenism | PCOS, oral contraceptive changes, postpartum effluvium, early-onset FPHL | Evaluate for signs of hyperandrogenism; fertility considerations in treatment |
| Perimenopause (40-55) | Declining estrogen, relative androgen excess | Accelerating FPHL, chronic telogen effluvium, thyroid dysfunction | Hormonal transition may unmask genetic predisposition; thyroid screening important |
| Postmenopause (>55) | Low estrogen, continued androgen effect | Progressive FPHL, senescent alopecia, medication effects | May progress more rapidly; review medications; consider HRT implications |
| Postpartum (0-6 months post-delivery) | Rapid estrogen decline | Postpartum telogen effluvium | Self-limiting; reassurance; rule out thyroiditis and iron deficiency |
Key Concept: The Three Primary Mechanisms
In gynecological practice, hair thinning typically results from one or more of three primary mechanisms:
- Androgen-mediated follicular miniaturization — The hallmark of female pattern hair loss; genetic susceptibility determines which follicles respond to androgens
- Telogen effluvium — Premature synchronized shedding triggered by hormonal shifts, stress, nutritional deficiency, or systemic illness
- Nutritional and metabolic factors — Iron deficiency, thyroid dysfunction, and vitamin D deficiency are commonly overlooked contributors
These mechanisms frequently coexist, and comprehensive evaluation should consider all three pathways.
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of hair thinning in women
Understanding the pathophysiology of hair loss is essential for targeted treatment. The hair follicle undergoes continuous cycling through growth (anagen), regression (catagen), and rest (telogen) phases. Disruption of this cycle—whether through hormonal influences, inflammatory processes, or metabolic disturbances—manifests clinically as hair thinning. In women, the interplay between androgens, estrogens, and follicular sensitivity creates a complex pathophysiological landscape that differs significantly from male pattern baldness.
The Hair Growth Cycle
| Phase | Duration | Characteristics | Clinical Relevance |
|---|---|---|---|
| Anagen (Growth Phase) | 2-7 years (scalp) | Active cell division in hair matrix; determines hair length; 85-90% of scalp hairs normally in this phase | Shortened anagen = shorter, thinner hairs; androgens shorten anagen in susceptible follicles |
| Catagen (Regression Phase) | 2-3 weeks | Apoptosis-driven regression; hair shaft detaches from papilla; approximately 1% of hairs in this phase | Transitional phase; rarely clinically significant |
| Telogen (Resting Phase) | 2-4 months | Club hair remains in follicle; no active growth; normally 10-15% of scalp hairs | Increased telogen percentage = telogen effluvium; physiologic shedding of 50-100 hairs/day |
| Exogen (Shedding Phase) | Variable | Active release of telogen hair independent of new anagen hair growth | Abnormal exogen can cause increased shedding even without telogen effluvium |
Androgen Metabolism in the Hair Follicle
| Component | Function | Clinical Relevance |
|---|---|---|
| Testosterone | Circulating androgen; converted locally to dihydrotestosterone (DHT) | Elevated in PCOS, adrenal disorders; only 25% of women with FPHL have elevated testosterone |
| 5-Alpha Reductase | Enzyme converting testosterone to DHT; Type I in sebaceous glands, Type II in hair follicles | Increased activity in scalp of women with FPHL; target of finasteride/dutasteride |
| Dihydrotestosterone (DHT) | Most potent androgen at follicle; binds androgen receptor with 5× affinity of testosterone | Primary mediator of follicular miniaturization; causes shortened anagen and thinner hair shaft |
| Androgen Receptor | Nuclear receptor in dermal papilla cells; mediates androgen effects on follicle | Polymorphisms associated with FPHL susceptibility; target of antiandrogen therapies |
| Aromatase | Enzyme converting testosterone to estradiol; present in hair follicle | Higher levels in occipital scalp may explain relative sparing; protective role of estrogens |
Primary Pathophysiological Mechanisms
Follicular Miniaturization
Process: Progressive reduction in follicle size and hair shaft diameter over successive cycles
Mediators: DHT binding to androgen receptors in dermal papilla
Result: Terminal hairs (thick, pigmented) transform to vellus-like hairs (fine, unpigmented)
Clinical relevance: Hallmark of androgenic alopecia; explains diffuse thinning without actual hair count reduction
Premature Telogen Entry
Process: Systemic triggers cause synchronized shift of anagen hairs into telogen phase
Triggers: Hormonal changes (postpartum, OCP discontinuation), stress, fever, surgery, crash diets
Result: Increased daily shedding (>100 hairs/day) 2-4 months after trigger
Clinical relevance: Telogen effluvium; usually reversible; identify and address underlying trigger
Impaired Follicular Nutrition
Process: Deficiencies in iron, ferritin, vitamin D, zinc, or protein impair follicular function
Mechanism: Hair matrix has high metabolic demand; follicle is non-essential tissue for survival
Result: Reduced hair production, early catagen entry, increased fragility
Clinical relevance: Common comorbidity; ferritin < 70 ng/mL associated with increased shedding
How Specific Conditions Cause Hair Thinning
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| Female Pattern Hair Loss | Genetic predisposition to follicular androgen sensitivity; DHT causes progressive miniaturization; shortened anagen phase; women may have normal androgen levels but increased local 5-alpha reductase activity | Target androgen pathway (antiandrogens, 5-alpha reductase inhibitors); stimulate growth (minoxidil); address contributing factors |
| Polycystic Ovary Syndrome | Elevated ovarian and adrenal androgens; insulin resistance increases free testosterone by lowering sex hormone-binding globulin; hyperandrogenism directly impacts follicle | Address insulin resistance (metformin, lifestyle); antiandrogen therapy (spironolactone, oral contraceptives); combined approach most effective |
| Postpartum Telogen Effluvium | High estrogen during pregnancy prolongs anagen; postpartum estrogen drop triggers synchronized telogen entry; shedding peaks 2-4 months postpartum | Reassurance (self-limiting); optimize nutrition; rule out postpartum thyroiditis and iron deficiency; usually resolves by 12 months |
| Hypothyroidism | Thyroid hormone essential for anagen initiation and maintenance; low T3/T4 causes prolonged telogen and reduced hair matrix activity | Thyroid hormone replacement; hair typically recovers 6-12 months after normalization of thyroid function |
| Hyperthyroidism | Accelerated hair cycling leads to shortened anagen; diffuse thinning; fine, soft hair texture | Correct hyperthyroid state; hair regrowth follows thyroid normalization |
| Iron Deficiency | Iron required for DNA synthesis in rapidly dividing hair matrix cells; ferritin is cellular iron storage form; deficiency impairs follicular proliferation | Iron supplementation; target ferritin > 70 ng/mL for optimal hair growth; address underlying cause of deficiency |
| Oral Contraceptive Changes | OCPs with high progestational activity may have androgenic effects; discontinuation causes estrogen withdrawal and telogen effluvium; androgenic progestins can worsen FPHL | Choose OCPs with low androgenic potential (norgestimate, desogestrel); drospirenone has antiandrogenic properties; counsel about post-discontinuation shedding |
| Perimenopause/Menopause | Declining estrogen removes protective effect against androgens; relative hyperandrogenism; decreased aromatase activity in follicle | Consider hormone replacement therapy (may help hair); topical minoxidil; spironolactone; address nutritional factors |
The Protective Role of Estrogens
Estrogen Effects on Hair Follicle
- Prolongs anagen phase: Explains improved hair quality during pregnancy
- Increases aromatase activity: Converts androgens to estrogens locally
- Increases sex hormone-binding globulin: Reduces free testosterone availability
- Direct follicular effects: Estrogen receptors present in dermal papilla
Clinical Scenarios of Estrogen Change
- Pregnancy: High estrogen prolongs anagen → thicker hair
- Postpartum: Estrogen withdrawal → synchronized telogen entry
- OCP discontinuation: Loss of exogenous estrogen → shedding
- Menopause: Estrogen decline → acceleration of FPHL
Often Overlooked Mechanism: The “Dual Hit” Phenomenon
Many women presenting with hair thinning have both androgenic alopecia and chronic telogen effluvium occurring simultaneously. The telogen effluvium (from stress, nutritional deficiency, or hormonal changes) unmasks or accelerates underlying female pattern hair loss. Treating only one component often leads to incomplete response. A comprehensive approach should address:
- The underlying androgenic component (antiandrogens, minoxidil)
- Any telogen effluvium triggers (nutrition, stress, thyroid, iron)
- The psychological impact that may perpetuate the stress-hair loss cycle
The Inflammatory Component
Recent research has identified a low-grade inflammatory process in androgenic alopecia, characterized by:
- Perifollicular lymphocytic infiltrates in early lesions
- Increased prostaglandin D2 (inhibits hair growth) in balding scalp
- Fibrosis of follicular sheath in advanced cases
This may explain why some patients respond to anti-inflammatory adjuncts and why early intervention before fibrosis is important for optimal outcomes.
3. History Taking
A comprehensive approach to eliciting the hair loss history in women
Red Flags — Require Urgent Evaluation
- Rapid onset virilization — Deepening voice, clitoromegaly, increased muscle mass (suggests androgen-secreting tumor)
- Severe, rapidly progressive hair loss — May indicate alopecia areata, scarring alopecia, or malignancy
- Scalp pain, burning, or tenderness — Suggests inflammatory or scarring alopecia requiring biopsy
- Visible scarring or skin changes — Indicates cicatricial alopecia; needs dermatology referral
- Associated severe headaches or visual changes — May indicate pituitary tumor (prolactinoma)
- Signs of Cushing syndrome — Moon facies, striae, central obesity, proximal weakness
- Sudden patchy hair loss — Alopecia areata; may indicate autoimmune disease
- Weight loss, night sweats, fever — Systemic illness, malignancy, or severe thyroid disease
Systematic History: The “THINHAIR” Approach
Use the mnemonic “THINHAIR” to ensure comprehensive history taking for hair loss:
- T — Timeline and Triggers: When did it start? What was happening in your life 2-4 months before onset? Any identifiable triggers?
- H — Hormonal History: Menstrual regularity, pregnancies, menopause status, contraceptive use, fertility treatments
- I — Intake and Iron: Diet quality, weight changes, vegetarian/vegan status, heavy menstrual bleeding, history of anemia
- N — Nature of Loss: Shedding vs. thinning? Diffuse or patchy? Where is it most noticeable? Hair texture changes?
- H — Hyperandrogenism Signs: Acne, hirsutism, oily skin, irregular periods, weight gain, skin darkening
- A — Associated Conditions: Thyroid disease, autoimmune conditions, PCOS, recent illness, surgery, or fever
- I — Inheritance: Family history of hair loss in mother, sisters, maternal grandmother, aunts
- R — Rx and Remedies: Current medications, supplements, previous hair loss treatments and their response
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Female Pattern Hair Loss | Gradual onset, central thinning, preserved hairline, family history | “Has your part gotten wider over time? Can you see more scalp through your hair than before? Does your mother or grandmother have thin hair?” |
| Telogen Effluvium | Acute diffuse shedding, identifiable trigger 2-4 months prior | “Are you finding more hair in the shower drain or on your pillow? Did anything significant happen 2-4 months before this started—illness, surgery, stress, diet change, new medication?” |
| Polycystic Ovary Syndrome | Irregular periods, acne, hirsutism, weight gain, infertility | “Are your periods regular? Do you have unwanted facial or body hair? Have you noticed acne on your chin or jawline? Any difficulty getting pregnant?” |
| Thyroid Dysfunction | Fatigue, weight changes, temperature intolerance, dry skin/hair | “Have you noticed changes in your energy level, weight, or how you tolerate heat or cold? Is your skin or hair drier than usual? Any constipation or palpitations?” |
| Iron Deficiency | Heavy periods, fatigue, vegetarian diet, pale skin | “How heavy are your periods—do you soak through pads/tampons hourly or pass clots? Do you eat red meat? Do you feel tired or short of breath with activity?” |
| Postpartum Effluvium | Onset 2-4 months after delivery, diffuse shedding | “When did you deliver? Are you breastfeeding? Did you have any complications during pregnancy or delivery? Any excessive bleeding postpartum?” |
| Medication-Induced | Temporal relationship to new medication | “Have you started any new medications in the past 3-6 months? Any changes to birth control? Are you taking any supplements or herbal products?” |
| Nutritional Deficiency | Restrictive diet, weight loss surgery, eating disorder history | “Have you been on any diets recently? Have you lost weight intentionally or unintentionally? Have you had weight loss surgery? Do you restrict any food groups?” |
| Alopecia Areata | Sudden patchy loss, smooth circular patches, possible autoimmune history | “Did the hair loss happen suddenly? Are there smooth, round patches? Do you have any autoimmune conditions like thyroid disease, vitiligo, or lupus?” |
| Traction Alopecia | Hair loss at margins, history of tight hairstyles | “Do you wear your hair in braids, weaves, extensions, or tight ponytails frequently? Is the hair loss mainly around your hairline or temples?” |
Essential Gynecological History Elements
Menstrual History
- Cycle regularity: Irregular cycles suggest anovulation and possible PCOS
- Flow volume: Heavy bleeding contributes to iron deficiency
- Menarche age: Late menarche may indicate hormonal issues
- Menopausal status: Perimenopause often accelerates FPHL
- Last menstrual period: Rule out pregnancy before treatment
Reproductive History
- Recent pregnancy: Postpartum effluvium timing
- Pregnancy complications: Postpartum hemorrhage, thyroiditis
- Breastfeeding status: Affects treatment options and hormonal state
- Infertility history: May indicate PCOS or hormonal dysfunction
- Contraceptive history: Recent changes, type of progestin used
Medication and Social History
Medications That Cause Hair Loss
- Hormonal contraceptives with androgenic progestins — Levonorgestrel, norgestrel (can worsen FPHL)
- Anticoagulants — Heparin, warfarin (telogen effluvium)
- Antidepressants — SSRIs, lithium, valproic acid
- Antihypertensives — Beta-blockers, ACE inhibitors
- Retinoids — Isotretinoin, acitretin (dose-dependent)
- Antithyroid medications — Propylthiouracil, methimazole
- Cholesterol-lowering agents — Statins, fibrates
- Chemotherapy agents — Cause anagen effluvium
- Immunosuppressants — Methotrexate, leflunomide
- Testosterone/DHEA supplements — Direct androgenic effect
Social and Lifestyle History
- Stress level: Chronic stress triggers telogen effluvium and may worsen FPHL
- Diet and nutrition: Vegetarian/vegan, restrictive diets, protein intake
- Recent weight changes: Rapid weight loss triggers shedding
- Hair care practices: Heat styling, chemical treatments, tight styles
- Smoking: May accelerate hair aging and worsen FPHL
- Occupation: Stress levels, chemical exposures
- Sleep quality: Poor sleep affects hair cycle
- Exercise: Excessive exercise with caloric restriction
Assessing Psychological Impact
Hair loss significantly impacts quality of life in women. Important questions include:
- “How is the hair loss affecting your daily life and mood?”
- “Are you avoiding social situations because of your hair?”
- “Have you noticed changes in your self-esteem or confidence?”
- “Are you experiencing anxiety or depression related to this?”
Consider screening for depression and anxiety, and address psychological support as part of the comprehensive treatment plan.
4. Physical Examination
A systematic approach to examining women with hair thinning
Systematic Framework: Use the “Scalp-to-System” approach for complete examination of patients presenting with hair thinning. The examination should evaluate both the hair/scalp directly and systemic signs of underlying conditions.
General Inspection
- Overall appearance: Body habitus (obesity suggests PCOS/insulin resistance), cushingoid features, signs of systemic illness
- Hair distribution globally: Note facial hair, body hair pattern (hirsutism), eyebrow/eyelash thinning
- Skin quality: Dry skin (hypothyroidism), oily skin/acne (hyperandrogenism), pallor (anemia), vitiligo (autoimmune)
- Affect and demeanor: Signs of psychological distress, depression, or anxiety
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Blood Pressure | Hypertension | May indicate PCOS with metabolic syndrome, Cushing syndrome, or adrenal pathology |
| Heart Rate | Tachycardia or bradycardia | Tachycardia suggests hyperthyroidism or anemia; bradycardia suggests hypothyroidism |
| Weight/BMI | Obesity or underweight | Obesity: PCOS, insulin resistance; Underweight: nutritional deficiency, eating disorder |
| Temperature | Usually normal | Fever may indicate underlying infection or inflammatory condition |
Scalp and Hair Examination
Hair Density Assessment
- Part width: Compare central part width to occipital part; widening suggests female pattern hair loss
- Hair density by region: Evaluate crown, vertex, frontal, temporal, and occipital areas separately
- Hairline: Preserved in FPHL; receding in male-pattern variant (suggests hyperandrogenism)
- Miniaturized hairs: Look for variation in hair diameter; fine, short hairs interspersed with normal terminal hairs indicate miniaturization
Hair Pull Test
How to Perform the Hair Pull Test
- Grasp approximately 60 hairs between thumb and forefinger near the scalp
- Apply gentle, steady traction while sliding fingers along the hair shaft
- Count the number of hairs extracted
- Repeat in multiple areas (frontal, temporal, parietal, occipital)
Interpretation:
- Normal: 0-2 hairs per pull (less than 10% of grasped hairs)
- Positive (abnormal): Greater than 6 hairs per pull suggests active shedding (telogen effluvium or active alopecia areata)
Note: Ask patient not to wash hair for 24 hours before test; recent washing may yield false-negative results.
Scalp Skin Examination
| Finding | Description | Associated Conditions |
|---|---|---|
| Normal scalp skin | No erythema, scaling, or scarring; visible follicular ostia | Female pattern hair loss, telogen effluvium (non-scarring alopecias) |
| Diffuse scaling | Fine white or yellow scales throughout scalp | Seborrheic dermatitis, psoriasis; can contribute to hair shedding |
| Erythema and perifollicular scaling | Redness around follicles, follicular pustules | Folliculitis, early scarring alopecia (lichen planopilaris, frontal fibrosing alopecia) |
| Smooth, shiny patches | Complete hair loss with smooth skin, no visible follicles | Alopecia areata (exclamation point hairs at edges); cicatricial alopecia if scarred |
| Loss of follicular ostia | Absent follicular openings, skin appears smooth and scarred | Scarring (cicatricial) alopecia—requires dermatology referral and biopsy |
| Broken hairs at scalp level | Short, broken hair shafts, irregular lengths | Traction alopecia, trichotillomania, tinea capitis |
Examination for Signs of Hyperandrogenism
Skin Findings
- Acne: Inflammatory lesions on face (especially jawline and chin), chest, or back
- Oily skin: Increased sebum production
- Acanthosis nigricans: Velvety hyperpigmentation in skin folds (neck, axillae, groin)—indicates insulin resistance
- Skin tags: Multiple acrochordons, associated with insulin resistance
Hair Distribution
- Hirsutism: Assess using modified Ferriman-Gallwey score; terminal hair on upper lip, chin, chest, abdomen, back
- Male-pattern scalp loss: Bitemporal recession, vertex thinning
- Limb hair: Increased hair on forearms and lower legs
Signs of Virilization (Red Flags)
- Clitoromegaly: Clitoral width greater than 10 mm (suggests androgen-secreting tumor)
- Voice deepening: Irreversible sign of severe hyperandrogenism
- Increased muscle mass: Male-pattern muscle development
- Decreased breast size: Breast atrophy
Body Habitus
- Central obesity: Waist circumference greater than 88 cm suggests metabolic syndrome
- Cushingoid features: Moon facies, buffalo hump, striae, thin skin
- BMI: Calculate and document; obesity associated with PCOS and insulin resistance
Thyroid and Neck Examination
- Thyroid size: Goiter suggests thyroid dysfunction
- Thyroid nodules: Palpate for nodularity
- Lymphadenopathy: May suggest systemic disease, malignancy, or infection
- Thyroid-associated findings: Exophthalmos, lid lag (hyperthyroidism); periorbital edema, loss of lateral eyebrows (hypothyroidism)
Additional Systemic Examination
| System | What to Examine | Relevant Findings |
|---|---|---|
| Nails | Nail plate, nail bed, cuticles | Pitting (alopecia areata, psoriasis); koilonychia (iron deficiency); brittle nails (thyroid, nutritional) |
| Eyes | Eyebrows, eyelashes, periorbital area | Lateral eyebrow thinning (hypothyroidism); madarosis (alopecia areata); periorbital edema (thyroid) |
| Oral mucosa | Buccal mucosa, gums, tongue | Pallor (anemia); lichen planus lesions (may accompany lichen planopilaris) |
| Abdomen | Palpation, striae | Hepatomegaly; purple striae (Cushing syndrome); palpable ovarian mass (rare, tumor) |
| Extremities | Peripheral edema, reflexes | Edema (hypothyroidism, heart failure); delayed reflexes (hypothyroidism); tremor (hyperthyroidism) |
Expected Findings by Etiology
| Condition | Scalp/Hair Findings | Skin/Body Findings | Other Findings |
|---|---|---|---|
| Female Pattern Hair Loss | Widened central part, diffuse thinning on crown, preserved frontal hairline, hair diameter variability, negative pull test | Often normal; may have mild acne or hirsutism | Usually normal systemic examination |
| Telogen Effluvium | Diffuse thinning throughout scalp, positive pull test (greater than 6 hairs), normal scalp skin | May have pallor if due to anemia; signs of recent illness or stress | Findings related to trigger (thyroid, postpartum, etc.) |
| Polycystic Ovary Syndrome | FPHL pattern or male-pattern recession; may have both thinning and hirsutism | Hirsutism, acne, acanthosis nigricans, central obesity, skin tags | Elevated BMI, signs of insulin resistance |
| Hypothyroidism | Diffuse thinning, dry coarse hair texture, loss of lateral third of eyebrows | Dry skin, periorbital edema, cool pale skin | Goiter, bradycardia, delayed reflexes, weight gain |
| Hyperthyroidism | Diffuse thinning, fine soft hair texture | Warm moist skin, pretibial myxedema (Graves disease) | Goiter, exophthalmos, tachycardia, tremor, weight loss |
| Iron Deficiency | Diffuse thinning, positive pull test, hair may be dry and brittle | Pallor (conjunctival, palmar creases), koilonychia | Tachycardia, fatigue appearance |
| Alopecia Areata | Smooth circular patches, exclamation point hairs at margins, positive pull test at active edges | May have vitiligo or other autoimmune findings | Nail pitting in 10-20% of patients |
| Androgen-Secreting Tumor | Rapid-onset male-pattern hair loss | Severe hirsutism, acne, virilization (clitoromegaly, voice changes, muscle bulk) | Possible palpable adrenal or ovarian mass (rare) |
Important Teaching Point
Normal examination is common! Many causes of hair thinning, particularly female pattern hair loss and telogen effluvium, present with entirely normal systemic examination findings. The scalp may appear normal except for reduced hair density, and a negative hair pull test does not exclude female pattern hair loss. A normal examination does not exclude significant pathology—laboratory investigation is often required to identify underlying causes such as iron deficiency, thyroid dysfunction, or hormonal imbalances.
Role of Dermoscopy (Trichoscopy)
If available, dermoscopy (trichoscopy) can aid diagnosis by revealing:
- Hair diameter variability (greater than 20%): Hallmark of androgenic alopecia
- Yellow dots: Sebum-filled empty follicles (androgenic alopecia, alopecia areata)
- Exclamation point hairs: Characteristic of alopecia areata
- Perifollicular scaling: Suggests frontal fibrosing alopecia or lichen planopilaris
- Loss of follicular openings: Indicates scarring alopecia
Consider dermatology referral for trichoscopy if diagnosis is uncertain or scarring alopecia is suspected.
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
The differential diagnosis of hair thinning in women is broad, but a systematic approach based on pattern, onset, and associated features allows efficient narrowing of possibilities. In gynecological practice, the key is to distinguish between androgenic causes, hormonal fluctuations, nutritional deficiencies, and systemic conditions while identifying the subset of patients who require urgent evaluation for serious underlying pathology.
Acute Hair Loss (Onset Less Than 6 Months)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 70%) | Telogen Effluvium | Diffuse shedding 2-4 months after trigger; positive pull test; identifiable precipitant (stress, illness, surgery, medication change, crash diet) | None if trigger identified; investigate if no clear trigger |
| COMMON | Postpartum Telogen Effluvium | Onset 2-4 months after delivery; diffuse shedding; self-limiting over 6-12 months | Excessive fatigue, palpitations (rule out thyroiditis, anemia) |
| LESS COMMON (approximately 20%) | Alopecia Areata | Sudden patchy loss; smooth circular patches; exclamation point hairs; may have nail pitting | Rapid progression to alopecia totalis/universalis |
| LESS COMMON | Acute Thyroid Dysfunction | New-onset hypo- or hyperthyroidism; diffuse thinning with systemic symptoms | Severe symptoms, cardiac involvement, thyroid storm |
| UNCOMMON BUT SERIOUS (approximately 10%) | Anagen Effluvium | Rapid hair loss within days to weeks; associated with chemotherapy, radiation, or toxin exposure | Unexplained anagen effluvium without known exposure |
| UNCOMMON BUT SERIOUS | Secondary Syphilis | “Moth-eaten” patchy alopecia; may have rash, lymphadenopathy, mucosal lesions | High-risk sexual history; systemic symptoms |
| UNCOMMON BUT SERIOUS | Systemic Lupus Erythematosus | Diffuse or patchy loss; may have discoid lesions; other lupus manifestations | Malar rash, arthritis, renal involvement, photosensitivity |
Chronic Hair Thinning (Duration Greater Than 12 Months)
Step-by-Step Approach to Chronic Hair Thinning:
- Step 1: Determine the pattern — Is it diffuse (central scalp) or patchy? Is the hairline preserved or receding?
- Step 2: Look for signs of hyperandrogenism — Acne, hirsutism, irregular periods, acanthosis nigricans
- Step 3: Screen for the “Big Four” treatable causes — Iron deficiency, thyroid dysfunction, vitamin D deficiency, and hormonal imbalance
- Step 4: Assess for scarring — If follicular ostia are absent or skin appears scarred, refer to dermatology urgently
- Step 5: Consider combined etiologies — Many patients have FPHL plus chronic telogen effluvium or nutritional deficiency
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Female Pattern Hair Loss (Androgenic Alopecia) | 40-50% of chronic cases | Gradual central thinning; widened part; preserved frontal hairline; family history; hair diameter variability on examination |
| COMMON | Chronic Telogen Effluvium | 20-30% | Persistent diffuse shedding greater than 6 months; fluctuating course; often no identifiable trigger; may coexist with FPHL |
| COMMON | Iron Deficiency (with or without anemia) | Contributing factor in 30-40% | Ferritin less than 70 ng/mL; heavy menstrual bleeding; vegetarian diet; fatigue; may worsen underlying FPHL |
| LESS COMMON | Polycystic Ovary Syndrome | 10-15% | Irregular periods; hirsutism; acne; obesity; acanthosis nigricans; may have male-pattern recession |
| LESS COMMON | Thyroid Dysfunction | 5-10% | Hypo- or hyperthyroidism; diffuse thinning; dry/coarse or fine/soft hair texture; systemic symptoms |
| LESS COMMON | Vitamin D Deficiency | Contributing factor in 10-20% | Often asymptomatic; associated with telogen effluvium; may worsen FPHL; common in darker skin tones |
| LESS COMMON | Traction Alopecia | 5-10% | Hair loss at hairline and temples; history of tight hairstyles (braids, weaves, extensions, tight ponytails) |
| UNCOMMON | Frontal Fibrosing Alopecia | 2-5% (increasing incidence) | Progressive hairline recession; eyebrow loss; perifollicular erythema; predominantly postmenopausal women |
| UNCOMMON | Lichen Planopilaris | 1-3% | Patchy scarring alopecia; perifollicular scale and erythema; scalp tenderness; may have oral/skin lichen planus |
| UNCOMMON | Central Centrifugal Cicatricial Alopecia | 1-3% (more common in Black women) | Progressive scarring alopecia starting at vertex; history of chemical relaxers or heat styling |
| RARE BUT SERIOUS | Androgen-Secreting Tumor | Less than 1% | Rapid-onset virilization; very elevated testosterone (greater than 200 ng/dL); DHEA-S greater than 800 mcg/dL |
| RARE BUT SERIOUS | Hyperprolactinemia | Less than 1% | Galactorrhea; amenorrhea; visual field defects; headaches; elevated prolactin |
Pattern-Based Approach to Differential Diagnosis
Diffuse Thinning (Central Scalp)
Female pattern hair loss
Chronic telogen effluvium
Iron deficiency
Thyroid dysfunction
Vitamin D deficiency
Nutritional deficiency
Frontal/Temporal Recession
Male-pattern variant (hyperandrogenism)
Frontal fibrosing alopecia
Traction alopecia
PCOS-associated hair loss
Androgen-secreting tumor
Patchy Hair Loss
Alopecia areata
Tinea capitis
Trichotillomania
Secondary syphilis
Discoid lupus
Lichen planopilaris
Vertex/Crown Thinning
Female pattern hair loss
Central centrifugal cicatricial alopecia
Chronic telogen effluvium
PCOS-related thinning
Drug-Induced Hair Loss
| Drug or Drug Class | Mechanism | Characteristics | Time to Resolution After Stopping |
|---|---|---|---|
| Oral contraceptives with androgenic progestins | Androgenic progestins (levonorgestrel, norgestrel) can worsen FPHL; OCP discontinuation causes estrogen withdrawal telogen effluvium | Gradual thinning while on OCP; acute shedding after stopping | FPHL: ongoing; Post-OCP effluvium: 6-12 months |
| Anticoagulants (heparin, warfarin, DOACs) | Telogen effluvium; mechanism not fully understood | Diffuse shedding; onset weeks to months after initiation | 2-4 months after discontinuation |
| Antidepressants (SSRIs, SNRIs, lithium) | Telogen effluvium; possible effects on hair growth cycle | Diffuse thinning; variable onset | 3-6 months after discontinuation |
| Valproic acid | Telogen effluvium; may affect zinc and selenium levels; dose-dependent | Diffuse shedding; may cause curly hair to become straighter | 3-6 months; hair texture may also recover |
| Retinoids (isotretinoin, acitretin) | Telogen effluvium; dose-dependent; affects sebaceous glands and hair follicle | Diffuse thinning; dry hair; temporary | 2-4 months after stopping or reducing dose |
| Beta-blockers | Telogen effluvium; mechanism unclear | Diffuse shedding; usually mild | 2-4 months after discontinuation |
| ACE inhibitors | Telogen effluvium; may affect zinc levels | Diffuse thinning; less common than with beta-blockers | 2-4 months after discontinuation |
| Testosterone/DHEA supplements | Direct androgenic effect on susceptible follicles | Pattern similar to FPHL; may cause hirsutism concurrently | Variable; 6-12 months; may not fully reverse |
| Chemotherapy agents | Anagen effluvium; direct toxicity to rapidly dividing hair matrix cells | Rapid, severe hair loss within 1-3 weeks of treatment | Regrowth begins 1-3 months after completion |
| Methotrexate | Anagen effluvium at high doses; telogen effluvium at low doses | Dose-dependent; may see diffuse thinning or more severe loss | 2-4 months after stopping or reducing dose |
| Excess vitamin A | Telogen effluvium; hypervitaminosis A affects hair cycle | Diffuse shedding; may have dry skin, headache, hepatotoxicity | 2-4 months after reducing intake |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Widened central part, preserved hairline | Female pattern hair loss | Check ferritin, TSH, vitamin D; consider empiric minoxidil |
| Diffuse shedding 2-4 months after identifiable event | Telogen effluvium | Reassurance; address trigger; check ferritin, TSH if prolonged |
| Hair thinning + irregular periods + acne + hirsutism | Polycystic ovary syndrome | Total and free testosterone, DHEA-S, fasting glucose/insulin, pelvic ultrasound |
| Hair thinning + heavy periods + fatigue | Iron deficiency | Ferritin, CBC, iron studies; investigate cause of heavy bleeding |
| Diffuse thinning + cold intolerance + weight gain + fatigue | Hypothyroidism | TSH, free T4; thyroid antibodies if TSH abnormal |
| Hair thinning + heat intolerance + weight loss + palpitations | Hyperthyroidism | TSH, free T4, free T3 |
| Smooth circular patches with exclamation point hairs | Alopecia areata | Consider dermatology referral; screen for thyroid disease |
| Hairline recession + eyebrow loss in postmenopausal woman | Frontal fibrosing alopecia | Urgent dermatology referral for biopsy; scarring is irreversible |
| Rapid virilization + severe hair loss + clitoromegaly | Androgen-secreting tumor | Urgent: total testosterone, DHEA-S; imaging (pelvic ultrasound, adrenal CT) |
| Hair loss + galactorrhea + amenorrhea | Hyperprolactinemia | Prolactin level; if elevated, pituitary MRI |
| Hair loss at temples/hairline + history of tight braids | Traction alopecia | Counsel on hair practices; if early, hair may regrow; if scarred, permanent |
| Scalp tenderness + perifollicular erythema + loss of follicular ostia | Scarring alopecia (cicatricial) | Urgent dermatology referral for biopsy and treatment to prevent progression |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
The diagnostic workup for hair thinning in women should be guided by clinical findings and tailored to the individual patient. A baseline panel is recommended for most patients to screen for common treatable causes, while additional testing is reserved for those with specific clinical features suggesting underlying pathology. The goal is to identify modifiable contributing factors rather than exhaustive testing in every patient.
Baseline Investigations for All Patients with Hair Thinning
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Ferritin | Assess iron stores; most sensitive marker for iron deficiency affecting hair | Optimal for hair: greater than 70 ng/mL; Deficient: less than 30 ng/mL; “Normal” range may still be suboptimal for hair | Can be falsely elevated with inflammation; check CRP if suspected; recheck after iron supplementation |
| Complete blood count (CBC) | Detect anemia; assess for microcytic pattern suggesting iron deficiency | Low hemoglobin, low MCV (microcytic), low MCH | Anemia is late finding; ferritin drops before hemoglobin; don’t wait for anemia to treat |
| Thyroid-stimulating hormone (TSH) | Screen for thyroid dysfunction | Elevated: hypothyroidism; Suppressed: hyperthyroidism | If abnormal, add free T4 and T3; consider thyroid antibodies for autoimmune thyroid disease |
| Vitamin D (25-hydroxyvitamin D) | Deficiency associated with telogen effluvium and may worsen FPHL | Deficient: less than 20 ng/mL; Insufficient: 20-30 ng/mL; Optimal: 40-60 ng/mL | Very common deficiency; supplementation is low-risk and may help hair; recheck after 3 months |
| Zinc | Deficiency can cause telogen effluvium; common in vegetarians and those with malabsorption | Low: less than 60 mcg/dL | Can supplement empirically if diet is poor; excess can cause copper deficiency |
The “Hair Loss Panel” — Minimum Baseline Testing
For every woman presenting with hair thinning, consider ordering:
- Ferritin (target greater than 70 ng/mL)
- TSH
- Vitamin D
- CBC
This basic panel catches the most common treatable contributing factors and is cost-effective for initial evaluation.
Targeted Investigations by Suspected Etiology
If Suspecting Hyperandrogenism or Polycystic Ovary Syndrome
First-Line Tests
- Total testosterone: Elevated if greater than 70 ng/dL; very elevated (greater than 200 ng/dL) suggests tumor
- Free testosterone: More sensitive than total; elevated in PCOS even when total is normal
- Sex hormone-binding globulin (SHBG): Low in PCOS and insulin resistance; low SHBG increases free testosterone
- Dehydroepiandrosterone sulfate (DHEA-S): Elevated suggests adrenal source; very elevated (greater than 800 mcg/dL) suggests adrenal tumor
Second-Line Tests
- Fasting glucose and insulin: Calculate HOMA-IR for insulin resistance
- Hemoglobin A1c: Screen for prediabetes/diabetes
- Lipid panel: Metabolic syndrome screening
- Pelvic ultrasound: Polycystic ovarian morphology; also to exclude ovarian tumor if testosterone very elevated
- 17-hydroxyprogesterone: If suspecting non-classic congenital adrenal hyperplasia (elevated morning level)
If Suspecting Thyroid Dysfunction
First-Line Tests
- TSH: Primary screening test
- Free T4: Order if TSH abnormal; confirms hypo- or hyperthyroidism
Second-Line Tests
- Free T3: If hyperthyroidism suspected (T3 toxicosis)
- Thyroid peroxidase antibodies (TPO-Ab): Hashimoto thyroiditis
- Thyroglobulin antibodies: Autoimmune thyroid disease
- TSH receptor antibodies: Graves disease
If Suspecting Iron Deficiency
First-Line Tests
- Ferritin: Most sensitive; target greater than 70 ng/mL for optimal hair growth
- CBC: Hemoglobin, MCV, MCH for microcytic anemia
Second-Line Tests
- Serum iron, TIBC, transferrin saturation: If ferritin borderline or elevated with inflammation
- C-reactive protein (CRP): Rule out inflammation falsely elevating ferritin
- Reticulocyte hemoglobin content: Early iron deficiency marker
- Investigate source: Heavy menstrual bleeding evaluation, GI workup if indicated
If Suspecting Other Hormonal Causes
Hyperprolactinemia
- Prolactin level: Elevated if greater than 25 ng/mL; very elevated (greater than 200 ng/mL) suggests prolactinoma
- Pituitary MRI: If prolactin significantly elevated to evaluate for adenoma
Cushing Syndrome
- 24-hour urinary free cortisol: Elevated in Cushing
- Late-night salivary cortisol: Convenient screening
- Overnight dexamethasone suppression test: 1 mg at 11 PM, check 8 AM cortisol
If Suspecting Autoimmune or Inflammatory Causes
Alopecia Areata/Autoimmune Screen
- TSH and thyroid antibodies: Associated autoimmune thyroid disease
- CBC: Rule out pernicious anemia
- Vitamin B12: Associated deficiency
- Consider ANA: If other autoimmune symptoms present
Systemic Lupus Erythematosus
- Antinuclear antibody (ANA): Screening test
- Anti-dsDNA, anti-Smith antibodies: More specific for lupus
- Complement levels (C3, C4): Low in active lupus
- Urinalysis: Screen for renal involvement
When to Order Advanced or Specialized Testing
| Clinical Scenario | Test to Consider | Rationale |
|---|---|---|
| Total testosterone greater than 200 ng/dL or DHEA-S greater than 800 mcg/dL | Pelvic ultrasound and adrenal CT/MRI | Rule out androgen-secreting tumor (ovarian or adrenal) |
| Suspected scarring alopecia (loss of follicular ostia, scalp tenderness) | Scalp biopsy by dermatology | Definitive diagnosis; distinguishes between types of cicatricial alopecia |
| Uncertain diagnosis between FPHL and chronic telogen effluvium | Trichoscopy (dermoscopy) or scalp biopsy | Hair diameter variability favors FPHL; increased telogen count on biopsy confirms TE |
| Young woman with FPHL and no family history | Comprehensive hormonal panel including 17-OH progesterone | Rule out non-classic congenital adrenal hyperplasia |
| Hair loss with cushingoid features | Cortisol testing (24-hour urine, salivary, or dexamethasone suppression) | Exclude Cushing syndrome |
| Patchy hair loss with high-risk history | RPR/VDRL for syphilis | Secondary syphilis can cause “moth-eaten” alopecia |
| Hair loss not responding to standard treatment | Repeat ferritin, TSH; consider scalp biopsy | Reassess for untreated contributing factors or alternative diagnosis |
Empiric Treatment Trials as Diagnostic Tools
Sequential Empiric Therapy Approach
When diagnosis is uncertain or multiple contributing factors are suspected, empiric treatment trials can serve as both diagnostic and therapeutic tools. Response to therapy supports the diagnosis and guides ongoing management.
- Iron supplementation trial: If ferritin less than 70 ng/mL, supplement and reassess hair shedding at 3-6 months. Improvement supports iron deficiency as contributor.
- Vitamin D supplementation trial: If level less than 40 ng/mL, supplement to achieve 40-60 ng/mL. Low risk intervention; reassess at 3 months.
- Minoxidil trial: For suspected female pattern hair loss, a 6-12 month trial of topical minoxidil 5%. Response supports diagnosis; lack of response may indicate alternative diagnosis.
- Antiandrogen trial: For suspected hyperandrogenic component with PCOS features, trial of spironolactone for 6-12 months (with contraception). Improvement supports androgen-mediated hair loss.
- Proton pump inhibitor trial: If suspect malabsorption affecting nutrient status, empiric PPI cessation (if on one) or evaluation for celiac/GI issues.
Laboratory Interpretation Pearls
- Ferritin “normal” range is misleading: Laboratory normal ranges (often 12-150 ng/mL) reflect population distribution, not optimal levels for hair. Target greater than 70 ng/mL for hair complaints.
- Free testosterone is more useful than total: SHBG fluctuations affect total testosterone; free testosterone reflects bioavailable androgen.
- Ferritin can be falsely elevated: Inflammation, infection, liver disease, and malignancy elevate ferritin. Check CRP if ferritin seems inappropriately normal/high in someone with suspected deficiency.
- Timing of blood draw matters for hormones: Testosterone, DHEA-S, and 17-OH progesterone should be drawn in the morning (8-10 AM) for accurate results.
- PCOS is a clinical diagnosis: Labs may be normal in PCOS. Diagnosis is based on Rotterdam criteria (2 of 3: oligo/anovulation, hyperandrogenism clinical or biochemical, polycystic ovaries on ultrasound).
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways for hair thinning in women
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Rapid virilization (voice deepening, clitoromegaly, muscle bulk increase) | EMERGENT | Same-day testosterone, DHEA-S; urgent pelvic ultrasound and adrenal imaging; gynecology/endocrinology referral |
| Scalp tenderness with visible scarring or loss of follicular ostia | EMERGENT | Urgent dermatology referral for biopsy; scarring alopecia is irreversible if untreated |
| Severe rapid hair loss with systemic symptoms (fever, weight loss, night sweats) | URGENT | Comprehensive workup for malignancy, autoimmune disease, severe infection; CBC, CMP, inflammatory markers, imaging as indicated |
| New alopecia areata with rapid progression | URGENT | Dermatology referral within 1-2 weeks; early treatment may prevent progression to alopecia totalis |
| Postpartum hair loss with severe fatigue, palpitations, mood changes | URGENT | TSH (postpartum thyroiditis), CBC and ferritin (postpartum anemia), mood assessment; treat underlying cause |
| Gradual diffuse thinning without red flags | ROUTINE | Baseline workup (ferritin, TSH, vitamin D, CBC); initiate treatment based on findings; follow-up in 3-6 months |
| Classic female pattern hair loss pattern, no systemic symptoms | ROUTINE | Baseline labs; consider empiric minoxidil; address modifiable factors; reassess in 6-12 months |
Step 2: Classify by Onset and Duration
Acute Onset (Less than 6 months)
Key question: Was there a trigger 2-4 months before onset?
Proceed to Algorithm A
Subacute (6-12 months)
Key question: Is shedding ongoing or has pattern emerged?
Proceed to Algorithm B
Chronic (Greater than 12 months)
Key question: Is this patterned thinning or ongoing diffuse loss?
Proceed to Algorithm C
Step 3: Follow the Appropriate Algorithm
Algorithm A: Acute Hair Shedding
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Diffuse shedding 2-4 months after delivery | Postpartum telogen effluvium | Reassurance (self-limiting); check TSH and ferritin; optimize nutrition; expect resolution by 12 months postpartum |
| Diffuse shedding after severe illness, surgery, or high fever | Telogen effluvium (post-illness) | Reassurance; baseline labs; address any nutritional deficiencies; expect recovery in 3-6 months |
| Diffuse shedding after starting new medication | Drug-induced telogen effluvium | Review medication list; discuss with prescriber about alternatives if possible; if medication essential, reassure that hair often adapts |
| Diffuse shedding after stopping oral contraceptives | Post-OCP telogen effluvium | Reassurance; typically resolves in 6-12 months; may unmask underlying FPHL—monitor pattern |
| Diffuse shedding after crash diet or significant weight loss | Nutritional telogen effluvium | Nutritional counseling; check ferritin, zinc, vitamin D, protein intake; supplement as needed |
| Sudden smooth circular patches | Alopecia areata | Dermatology referral; check thyroid function; consider intralesional steroids or topical immunotherapy |
| Acute severe shedding with no clear trigger | Acute telogen effluvium (trigger may not be apparent) | Comprehensive workup: TSH, ferritin, CBC, vitamin D, ANA; consider scalp biopsy if uncertain; reassess in 3 months |
Algorithm B: Subacute Hair Loss (6-12 Months)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Ongoing diffuse shedding, no clear pattern emerging | Chronic telogen effluvium or persistent trigger | Recheck ferritin (target greater than 70), TSH, vitamin D; evaluate for chronic stress, dietary issues, occult illness |
| Central thinning becoming apparent, reduced shedding | Emerging female pattern hair loss | Start minoxidil 5% topical; address nutritional factors; consider antiandrogen if hyperandrogenic features |
| Hair loss with new irregular periods, acne, or hirsutism | Polycystic ovary syndrome | Hormonal workup (testosterone, DHEA-S, SHBG); glucose/insulin; pelvic ultrasound; treat underlying PCOS |
| Hair loss with fatigue, weight changes, temperature intolerance | Thyroid dysfunction | TSH, free T4, thyroid antibodies; treat thyroid disease; hair typically improves 6-12 months after euthyroid state achieved |
| Hair loss with heavy menstrual bleeding | Iron deficiency contributing to hair loss | Ferritin, CBC, iron studies; address cause of heavy bleeding; iron supplementation to ferritin greater than 70 ng/mL |
Algorithm C: Chronic Hair Thinning (Greater than 12 Months)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Widened central part, preserved frontal hairline, family history positive | Female pattern hair loss | Minoxidil 5% topical daily; optimize ferritin greater than 70 ng/mL; consider spironolactone 100-200 mg daily if tolerant; set realistic expectations |
| Bitemporal recession with or without vertex thinning | Male-pattern variant (suggests hyperandrogenism) | Full androgen workup; rule out tumor if testosterone very elevated; antiandrogen therapy indicated; evaluate for PCOS |
| Ongoing fluctuating shedding without clear pattern | Chronic telogen effluvium (may coexist with FPHL) | Identify and address all contributing factors; may need ongoing nutritional optimization; consider low-dose minoxidil |
| Progressive hairline recession with eyebrow loss, postmenopausal | Frontal fibrosing alopecia | Urgent dermatology referral; scalp biopsy for confirmation; treatment to halt progression (cannot reverse scarring) |
| Hair loss at temples/hairline with history of tight hairstyles | Traction alopecia | Counsel on hair practices; if early (non-scarred), hair may regrow; if scarred, permanent loss—prevention of further damage |
| Vertex thinning in Black woman with history of relaxers/heat | Central centrifugal cicatricial alopecia | Dermatology referral; scalp biopsy; treatment to prevent progression; modify hair care practices |
Step 4: Pattern-Based Treatment Selection
| Pattern/Features | Primary Treatment Approach | Adjunctive Therapies |
|---|---|---|
| Classic FPHL pattern, no hyperandrogenism | Topical minoxidil 5% once daily | Optimize ferritin, vitamin D; low-level laser therapy; consider oral minoxidil if topical not tolerated |
| FPHL with PCOS features | Spironolactone 100-200 mg daily + minoxidil | Combined OCP with antiandrogenic progestin (drospirenone); metformin if insulin resistant; lifestyle modification |
| FPHL in postmenopausal woman | Minoxidil 5% + consider spironolactone | Discuss HRT implications; optimize nutrition; finasteride may be considered (off-label, no pregnancy risk) |
| Telogen effluvium (acute, trigger identified) | Address trigger; reassurance; watchful waiting | Nutritional optimization; stress management; no specific hair treatment usually needed |
| Chronic telogen effluvium | Identify and treat all contributing factors | Low-dose minoxidil may help; comprehensive nutritional panel; stress/sleep optimization |
| Iron deficiency contributing to hair loss | Iron supplementation (ferrous sulfate 325 mg with vitamin C) | Address source of deficiency; target ferritin greater than 70 ng/mL; recheck in 3 months |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient is pregnant and concerned about hair loss | Reassure that some shedding is normal; avoid minoxidil and antiandrogens during pregnancy | Check ferritin, TSH; optimize prenatal nutrition; counsel about expected postpartum shedding |
| Patient is breastfeeding with hair loss | Reassure (postpartum effluvium); avoid minoxidil and spironolactone while breastfeeding | Optimize nutrition; check thyroid and iron; can start treatment after weaning if needed |
| Patient wants to conceive and is on spironolactone | Stop spironolactone at least 1 month before attempting conception (teratogenic—feminizes male fetus) | Continue minoxidil until pregnancy confirmed, then stop; optimize preconception health |
| Minoxidil causing unwanted facial hair growth | Counsel on application technique (apply to scalp only, wash hands immediately); consider reducing concentration or frequency | Switch to 2% if 5% not tolerated; consider oral minoxidil as alternative; facial hair is reversible after stopping |
| Patient experiences increased shedding after starting minoxidil | Reassure—this is expected “dread shed” as miniaturized hairs are pushed out; typically lasts 2-8 weeks | Encourage continuation; improvement expected by 4-6 months; if no improvement by 12 months, reassess diagnosis |
| Ferritin is “normal” at 35 ng/mL but patient has significant shedding | Treat as suboptimal for hair; initiate iron supplementation targeting ferritin greater than 70 ng/mL | Recheck ferritin in 3 months; investigate source if not improving despite supplementation |
| Patient has both FPHL and chronic telogen effluvium | Treat both: minoxidil for FPHL + address all TE triggers (nutrition, thyroid, stress) | Set realistic expectations; improvement may be gradual; multiple interventions often needed |
| Treatment not working after 12 months | Reassess diagnosis; repeat labs; ensure compliance; consider scalp biopsy if diagnosis uncertain | Consider alternative diagnosis; dermatology referral; discuss treatment escalation (oral minoxidil, combination therapy) |
Troubleshooting Refractory Hair Thinning
Ask These Questions When Treatment Is Not Working
- Is the patient using minoxidil correctly? Applied to dry scalp daily, not rinsed off for at least 4 hours, consistent use
- Has treatment duration been adequate? Minoxidil requires 4-6 months minimum, often 12 months for full effect
- Have all nutritional deficiencies been corrected? Recheck ferritin (greater than 70), vitamin D (greater than 40), zinc
- Is thyroid function truly optimized? TSH in lower half of normal range is optimal for hair
- Are there ongoing triggers for telogen effluvium? Chronic stress, poor sleep, restrictive eating, new medications
- Is the diagnosis correct? Consider scalp biopsy if not classic presentation; may be scarring alopecia
- Are there multiple overlapping causes? FPHL + chronic TE + nutritional deficiency is common
- Has an androgen-secreting tumor been ruled out? If hyperandrogenic features, recheck testosterone
- Would the patient benefit from combination therapy? Minoxidil + spironolactone + nutritional optimization
- Is psychological support needed? Anxiety about hair loss can perpetuate stress-related shedding
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Ferritin greater than 70 is the target: Laboratory “normal” ranges for ferritin (often 12-150 ng/mL) do not reflect optimal levels for hair growth. Hair shedding often improves when ferritin exceeds 70 ng/mL, even if the patient was never technically “deficient.”
The “dual hit” is common: Many women have both female pattern hair loss AND chronic telogen effluvium occurring simultaneously. Treating only one component leads to incomplete response. Always look for and address multiple contributing factors.
Minoxidil works—but takes time: Patients must be counseled that minoxidil requires 4-6 months minimum to show benefit, and 12 months for full effect. Early “dread shed” (increased shedding in first 2-8 weeks) is actually a good sign that the medication is working.
Normal androgens don’t rule out androgenic alopecia: The majority of women with female pattern hair loss have normal serum androgen levels. The pathology is at the follicular level—increased local 5-alpha reductase activity and androgen receptor sensitivity.
Ask about the 2-4 month window: Telogen effluvium presents 2-4 months after the triggering event. When taking history, specifically ask what was happening in the patient’s life 2-4 months before the shedding began—not when it started.
Postpartum shedding is self-limiting: Postpartum telogen effluvium, while distressing, resolves spontaneously by 12 months in most women. Reassurance is the primary treatment. However, always check TSH (postpartum thyroiditis) and ferritin (postpartum anemia).
Scarring alopecia is a dermatological emergency: If you see loss of follicular ostia, scalp tenderness, or perifollicular erythema, refer urgently to dermatology. Scarring alopecia is irreversible once fibrosis occurs—early intervention is critical.
Choose contraceptives wisely: For women with or at risk for androgenic alopecia, avoid oral contraceptives with androgenic progestins (levonorgestrel, norgestrel). Prefer pills containing drospirenone, norgestimate, or desogestrel, which have lower androgenic potential.
Critical Pitfalls to Avoid
Dismissing hair loss as “just cosmetic”: Hair loss causes significant psychological distress, depression, and reduced quality of life. Take the complaint seriously, perform appropriate workup, and provide treatment and support.
Accepting “normal” ferritin as adequate: A ferritin of 15-30 ng/mL is technically within normal range but is suboptimal for hair. Don’t tell a patient with a ferritin of 25 that “your iron is fine”—supplement to achieve greater than 70 ng/mL.
Missing the diagnosis of scarring alopecia: Frontal fibrosing alopecia and other cicatricial alopecias are increasingly common and can be mistaken for female pattern hair loss. Look carefully at the hairline and for loss of follicular openings. Delay in diagnosis means permanent, irreversible hair loss.
Starting spironolactone without contraception counseling: Spironolactone is teratogenic (feminizes male fetuses). Always ensure reliable contraception is in place before prescribing, and counsel patients to stop the medication before attempting pregnancy.
Stopping minoxidil too early: Patients often discontinue minoxidil at 3-4 months because they don’t see improvement or experience initial shedding. Counsel upfront that 6-12 months is needed, and that early shedding is expected and temporary.
Failing to warn about post-OCP shedding: When discontinuing oral contraceptives, counsel patients that telogen effluvium may occur 2-4 months later. This prevents unnecessary panic and workup when it occurs.
Not recognizing rapid virilization as an emergency: A woman presenting with rapid-onset hair loss plus voice deepening, clitoromegaly, or significant new hirsutism may have an androgen-secreting tumor. This requires urgent evaluation—do not wait for routine follow-up.
Ordering unnecessary extensive workups: For classic female pattern hair loss without systemic symptoms, extensive hormonal panels are not needed. A basic panel (ferritin, TSH, vitamin D, CBC) is sufficient. Save comprehensive testing for patients with hyperandrogenic features or atypical presentations.
Key Takeaways
- Female pattern hair loss is the most common cause of chronic hair thinning in women, affecting up to 50% of women by age 50. It is characterized by progressive central thinning with preservation of the frontal hairline.
- The “Big Four” treatable contributing factors should be assessed in every patient: iron deficiency (ferritin less than 70 ng/mL), thyroid dysfunction, vitamin D deficiency, and hormonal imbalance.
- Telogen effluvium and female pattern hair loss commonly coexist. A comprehensive approach addressing both components yields better outcomes than treating either alone.
- Topical minoxidil 5% is first-line treatment for female pattern hair loss. It requires 4-6 months for initial effect and 12 months for full benefit. Patients should be warned about initial “dread shed.”
- Spironolactone is an effective antiandrogen for women with androgenic alopecia, especially those with PCOS features. Always ensure reliable contraception due to teratogenicity.
- Postpartum telogen effluvium is self-limiting and typically resolves by 12 months. Reassurance is key, but screen for postpartum thyroiditis and iron deficiency.
- Red flags requiring urgent evaluation include rapid virilization (possible androgen-secreting tumor), scalp scarring or loss of follicular ostia (cicatricial alopecia), and systemic symptoms suggesting serious underlying disease.
- The psychological impact of hair loss is significant and should not be minimized. Address emotional wellbeing as part of comprehensive management.
- Early intervention produces better outcomes. Miniaturized follicles can be rescued with treatment, but once the follicle is completely atrophied, hair loss is permanent.
- Set realistic expectations: treatment can stabilize hair loss and produce modest regrowth, but returning to pre-loss density is rarely achievable. The goal is to maintain what the patient has and improve where possible.
Quick Reference Algorithm
Systematic Approach to Hair Thinning in Women:
- Identify urgency: Screen for red flags (rapid virilization, scarring, systemic symptoms) requiring immediate referral or workup
- Characterize the hair loss: Determine onset (acute vs. chronic), pattern (diffuse vs. patterned vs. patchy), and associated symptoms
- Take a focused history: Use the “THINHAIR” mnemonic—Timeline/Triggers, Hormonal history, Intake/Iron, Nature of loss, Hyperandrogenism signs, Associated conditions, Inheritance, Rx/Remedies
- Perform targeted examination: Evaluate scalp (pattern, scarring, pull test), signs of hyperandrogenism (acne, hirsutism, acanthosis), and thyroid
- Order baseline investigations: Ferritin (target greater than 70 ng/mL), TSH, vitamin D, CBC for all patients; add androgen panel if hyperandrogenic features present
- Establish the diagnosis: Female pattern hair loss, telogen effluvium, PCOS-related, or other—often multiple contributing factors
- Initiate treatment: Address all modifiable factors (optimize ferritin, vitamin D, thyroid); start minoxidil for FPHL; add spironolactone if indicated; refer to dermatology if scarring or uncertain diagnosis
- Set expectations and follow up: Counsel on timeline (6-12 months for improvement), monitor response, adjust treatment as needed, and provide psychological support